Contineum Therapeutics Statistics

Total Valuation

CTNM has a market cap or net worth of $100.38 million. The enterprise value is -$84.33 million.

Market Cap	100.38M
Enterprise Value	-84.33M

Important Dates

The next estimated earnings date is Tuesday, August 12, 2025, after market close.

Earnings Date	Aug 12, 2025
Ex-Dividend Date	n/a

Share Statistics

CTNM has 25.87 million shares outstanding. The number of shares has increased by 981.89% in one year.

Current Share Class	19.14M
Shares Outstanding	25.87M
Shares Change (YoY)	+981.89%
Shares Change (QoQ)	+0.21%
Owned by Insiders (%)	2.02%
Owned by Institutions (%)	38.20%
Float	13.17M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.54
P/TBV Ratio	0.54
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 21.47, with a Debt / Equity ratio of 0.03.

Current Ratio	21.47
Quick Ratio	21.31
Debt / Equity	0.03
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -33.03% and return on invested capital (ROIC) is -23.95%.

Return on Equity (ROE)	-33.03%
Return on Assets (ROA)	-22.94%
Return on Invested Capital (ROIC)	-23.95%
Return on Capital Employed (ROCE)	-31.20%
Revenue Per Employee	n/a
Profits Per Employee	-$1.22M
Employee Count	41
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -81.25% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-81.25%
50-Day Moving Average	4.12
200-Day Moving Average	10.24
Relative Strength Index (RSI)	45.76
Average Volume (20 Days)	213,230

Short Selling Information

The latest short interest is 774,117, so 2.99% of the outstanding shares have been sold short.

Short Interest	774,117
Short Previous Month	600,754
Short % of Shares Out	2.99%
Short % of Float	5.88%
Short Ratio (days to cover)	6.13

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-59.07M
Pretax Income	n/a
Net Income	-49.83M
EBITDA	-58.80M
EBIT	-59.07M
Earnings Per Share (EPS)	-$1.98

Full Income Statement

Balance Sheet

The company has $190.71 million in cash and $6.00 million in debt, giving a net cash position of $184.71 million or $7.14 per share.

Cash & Cash Equivalents	190.71M
Total Debt	6.00M
Net Cash	184.71M
Net Cash Per Share	$7.14
Equity (Book Value)	184.77M
Book Value Per Share	7.14
Working Capital	183.19M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$39.28 million and capital expenditures -$414,000, giving a free cash flow of -$39.70 million.

Operating Cash Flow	-39.28M
Capital Expenditures	-414,000
Free Cash Flow	-39.70M
FCF Per Share	-$1.53

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

CTNM does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-981.89%
Shareholder Yield	-981.89%
Earnings Yield	-49.64%
FCF Yield	-39.55%

Analyst Forecast

The average price target for CTNM is $22.50, which is 479.90% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$22.50
Price Target Difference	479.90%
Analyst Consensus	Strong Buy
Analyst Count	4
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2